Towia A Libermann, PhD
Principal Investigator
Interdisciplinary Medicine and Biotechnology
Contact Information
| Office: | RN-0380C |
| Phone: | 617-667-0760 |
| Fax: | 617-667-0891 |
| Email: | tliberma@bidmc.harvard.edu |
| Address: | 330 Brookline Ave; RN-0380C
Boston, MA 02215 |
Advanced Degree And Training
| Year | Institution | Area or Rank |
| 1986 | Weizmann Institute of Science and Technology | Immunology |
| 1986 | Biotechnology Research Center Rorer | Senior Investigator |
| 1987 | Whitehead Institute for Biomedical Research | Postdoctoral fellow |
| 1990 | BIDMC | Instructor |
| 1992 | BIDMC | Assistant Professor |
| 2000 | BIDMC | Associate Professor |
Research Lab Team Members
| Simon Dillon PhD | Xuesong Gu PhD |
Areas of Interest
| 1 Cancer |
Major Research Theme
|
Summary: Dr. Libermann is the director of the BIDMC Genomics Center and of the DF/HCC Cancer Proteomics Core, which provide core assistance to medical center investigators in the use of various proteomics, genomics and bioinformatics technologies. The Libermann laboratory focuses on both basic science and translational research with a particular focus on genomics and proteomics Systems Biology approaches to human disease. The laboratory is applying various cutting edge technologies for proteomics, transcriptional profiling and genotyping in order to define and compare protein and gene profiles and genomic DNA in kidney, ovarian, prostate, liver and breast cancer tissues and bodily fluids, correlate protein and gene profiles and mutations with biological activities and disease, define disease mechanisms at a molecular level and predict clinical outcome and response to therapy. Additional interests of the lab are to dissect the molecular mechanisms of drug action in order to rationally design combination therapies for cancer, understanding escape from programmed cell death in cancer cells and the role of Ets transcription factors in cancer. New efforts to develop novel proteomics methods for biomarker discovery and validation are in progress. Discovery and validation of biomarkers and therapeutic targets in renal cell cancer Renal Cell Cancer (RCC) is the most lethal of the urological cancers. Despite numerous recent advances in diagnostic imaging, surgical therapy and basic molecular understanding there is still a considerable number of patients suffering and dying from metastatic disease. The recent development of novel targeted therapies based on the precise biological pathways deregulated in a particular patient has paved the way for individualized, targeted patient management. Nevertheless, to achieve this goal it is of utmost importance to delineate the molecular mechanisms underlying cancer development and progression. Genomics and proteomics approaches have revolutionized the field of cancer research and have led to rapid discovery of multiple, parallel disease hypotheses that ultimately have to be validated in large cohorts of patients and in downstream biological experiments for translation into clinical applications. The variable course of RCC and paucity of therapeutic options in the event of metastasis have led to the search for diagnostic and prognostic markers. The Libermann laboratory is using microarrays and mass spectrometry to classify different subtypes of RCC and to identify subtype- and metastasis-specific gene and protein signatures and biomarkers predictive for outcome and response to therapy. The effort is also focusing on identifying and validating emerging biological pathways underlying RCC development and progression and novel drug targets for therapeutic intervention. The goal is to improve management of patients with RCC by identifying the precise disease mechanisms for each individual patient and to devise targeted therapies. Systems biology of renal cell cancer Delineation of the genome and proteome has become the new frontier in many research areas including cancer as the result of completion of the human genome sequencing. In depth understanding of the cancer genome and proteome promises to solve many biological and clinical questions and is, therefore, considered an enabling and critical approach in cancer research and clinical investigation. Furthermore, each of these approaches may generate thousands of data points that require sophisticated bioinformatics and biostatistics analysis. It is becoming apparent that only if we understand the complexities of interactions of the genome and proteome within cells and in the extracellular compartments, will we be able to model the complex biological pathways in cancer. In particular in the context of cancer, mutations, deletions and fusions of proteins play central roles in the development and progression as well as response to therapy of cancer. Furthermore, deregulations of kinases, phosphatases, proteases, glycosidases, acetylases as well as various other protein modifying enzymes lead to complex, cancer-specific protein modifications. Genomics analyses of renal cell cancer (RCC) by the Libermann laboratory and others have revealed a variety of biological pathways and multiple specific gene sets that are deregulated in RCC, providing ample opportunities for validation and eventual targeted therapies against validated targets. However, in order to prioritize potential drug targets and to understand the biological and physiological consequences of disrupting the activity of a specific gene, it is necessary to carefully dissect the biological pathways of deregulated genes. The Libermann laboratory is applying a systems biology approach to systematically analyze the relevance of different genes and biological pathways and delineate the molecular mechanisms for RCC development and progression by combining genomic and proteomic approaches with gene knock-down and overexpression studies in cell culture and animal models as well as patient cohorts of RCC. A particular effort focuses on the role of tyrosine kinases in RCC. Identification of early detection and prognostic biomarkers in ovarian cancer Epithelial ovarian cancer (EOC) is a major cause of gynecologic cancer mortality. Most patients present with advanced disease that is managed with surgical cytoreduction, followed by postoperative chemotherapy. Standard chemotherapy with carboplatin in combination with a taxane results in an initial response rate of over 70%, although subsequent relapse frequently occurs and eventually becomes resistant to a wide variety of agents. Consequently, the long-term survival of patients with upper abdominal involvement (stage III) or those with disease beyond the abdomen (stage IV) ranges from 30% to less than 10%. Traditional clinical factors are reasonable but imperfect measures of outcome and response to therapy. While individual molecular markers carry some predictive and prognostic value, they have not by themselves been proven to be accurate enough for clinical application, suggesting that no single factor can serve as a surrogate for the complex genetic changes associated with tumor growth and response to chemotherapy. Similarly, the etiology of ovarian cancer is not yet well understood, despite the low 5-year survival of this disease. Relatively few plasma biomarkers have been examined in relation to ovarian cancer risk, and discovery of new protein risk factors has evolved slowly. However new genomic and proteomic technologies now permit the simultaneous evaluation of the whole genome or proteome. The Libermann laboratory is collaborating with S. Cannistra and S. Hankinson (Harvard School of Public Health) on identification and validation of gene and protein biomarkers for outcome, response to chemotherapy and early detection of ovarian cancer using ovarian cancer tumor tissue and serum in microarray and mass spectrometry based experiments. Gene signatures for outcome and chemoresponse were identified and the clinical relevance of specific biomarkers and biological pathways will now be validated to gain insight into the genetic, genomic and proteomic changes that are involved in ovarian cancer development, progression and response to therapy. Early detection biomarkers for liver cancer Hepatitis C is the commonest cause of chronic hepatitis in the United States and approximately 20 � 30% of patients with HCV will progress to cirrhosis and advanced fibrosis. Once HCV cirrhosis has developed patients are at risk for liver decompensation and hepatocellular carcinoma (HCC) at a variable rate of 2 � 7% per year. The national incidence of HCC is rising in the US and current screening practices of ultrasonography and tumor markers such as alpha-fetoprotein (AFP) are less than optimal for the early detection of HCC. In collaboration with N. Afdhal the Libermann laboratory utilizes cutting edge proteomics approaches to identify novel serum biomarkers that may be used for the early diagnosis of HCC. The overall goal is to develop better serological screening algorithms for HCC in patients with HCV cirrhosis and chronic liver diseases of any etiology. Biomarkers identified by the proteomic approach will then be validated by multiplex proteomics approaches to determine their potential clinical utility for the early non-invasive diagnosis and screening of HCC in at risk populations. Molecular mechanisms of anti-cancer drugs An increasing number of studies have demonstrated that some non-steroidal anti-inflammatory drugs (NSAIDs), at clinically tolerable concentrations, are effective in the treatment of several types of cancer. NSAIDs have been shown to reduce cancer proliferation and induce cancer apoptosis in vitro and in vivo. Nevertheless, the mechanisms of apoptosis induction are poorly understood and more studies are needed to fully elucidate the molecular and biochemical pathways of NSAID-induced apoptosis. The Libermann laboratory has started to dissect the molecular mechanisms involved in the apoptosis induction by various NSAIDs using genomics approaches to identify the biological pathways and genes that mediate the pro-apoptotic effect. The pro-apoptotic cytokine IL-24 and the GADD45 family were identified as critical mediators of NSAID-induced apoptosis in various types of cancer and further studies are elucidating the IL-24 pathway of apoptosis in detail. Understanding the molecular mechanisms involved in apoptosis induction by a panel of NSAIDs will be the first step in a systematic survey of NSAIDs with regard to their abilities to inhibit cancer growth and their particular mechanism of action and will provide opportunities for a rational design of new combination treatment modalities in cancer. Ets transcription factor translocations and deregulations in prostate cancer and other cancers The Libermann laboratory has focused for many years on the Ets family of transcription factors and has identified and characterized a set of new, epithelial-specific Ets factors whose roles in prostate cancer and other cancers is being explored. A major breakthrough for prostate cancer (PCa) was the identification of recurrent fusions between an androgen regulated gene (TMPRSS2) and at least three Ets transcription factors (ERG, ETV4 and ETV1) in up to 80% of primary and metastatic PCa patients, which placed the Ets factors under androgen stimulated regulation of TMPRSS2. Nevertheless, the functional consequences of these translocations for PCa are unknown, necessitating not only the search for drugs that inhibit their activities, but also a systematic approach to define their functions in PCa development and/or progression. The hypothesis is that Ets factor translocations play an essential role in PCa development and progression and a systematic analysis of the biological functions and molecular mechanisms of these Ets factors in PCa will provide new opportunities to target these factors or their affected biological pathways. The Libermann laboratory is trying to understand the role and biological relevance of Ets factor translocations in PCa. The laboratory uses various state-of-the-art technologies including RNA interference, genomics, proteomics, cell based assays and animal models to elucidate the pathophysiological consequences of Ets protein dysregulation in prostate cancer. Innovative proteomics methods for biomarker discovery and validation Proteomics approaches for biomarker discovery are notoriously unreliable due to low inter- and intra-experimental reproducibility. Furthermore, the broad dynamic range of protein expression in serum and other bodily fluids or tissues is another major challenge to identify low abundant biomarkers. The Libermann laboratory has initiated a novel multiplexed quantitative proteomics approach to identify and validate biomarkers in plasma and other bodily fluids that combines multidimensional protein and peptide fractionation, immunoaffinity enrichment, isobaric labeling for protein quantitation and mass spectrometry. The goal is to develop a new platform that is able to quantitate multiple biomarkers in multiple samples with high throughput, high sensitivity and high reproducibility. |
Publications
External Recognition
| Major Administrative Responsibilities: Local Year Name of Committee Role Institution 1992-1996 Immunology Seminar Series Organizer Beth Israel Deaconess Medical Center 1997-2003 Bone and Joint Seminar Series Organizer Beth Israel Deaconess Medical Center 1999- BIDMC Genomics Center Director Beth Israel Deaconess Medical Center 1999 Tolerance Pharmaceuticals, Inc. Founder and Beth Israel Scientific Advisor Deaconess Medical Center 2000 NIDDK Biotechnology Center Director Beth Israel Deaconess Medical Center 2001 Cardion Scientific Advisor and Share Holder 2002- Frontiers in Functional Genomics, Organizer Beth Israel Proteomics and Bioinformatics Deaconess Medical Seminar Series Center 2004- DF/HCC Cancer Proteomics Core Director Beth Israel Deaconess Medical Center 2005 TBK Pharmaceuticals Founder and Scientific Advisor 2006- Center for Individualized Medicine Co-Director Beth Israel Deaconess Medical Center 2007 AOC Committee for residents projects for Reviewer Beth Israel area of concentration (AOC) time Deaconess Medical Center 2007 Breast Cancer SPORE Developmental Reviewer Dana Farber/ Pilot Projects Harvard Cancer Center National Year Name of Committee Role Institution 1996-1998 Molecular Biology/Genetics Study Section Reviewer Arthritis Foundation 2008 AAAS Maine Technology Asset Fund Reviewer AAAS Government Year Name of Committee Role Institution 1992 Grants for Brain Tumor Research Ad Hoc Reviewer NIH-NINDS 1997 NSF Ad Hoc Reviewer NSF 1998 RFA for Euglycemia Reviewer NIH-NIDDK 2001 NIDDK Biotechnology Center Reviewer NIH-NIDDK 2001 Environmental Health Science Center, Reviewer NIH-NIEHS University of Cincinnati 2002 RFA for DNA Microarray Facilities Reviewer NIH-NHLBI 2003 Program Project Grant, Charleston, SC Reviewer NIH-NCI 2003 NCCAM Centers Program Reviewer NIH-NCCAM 2004 NIH Roadmap Reviewer NIH 2004 Program Project Grant, Charleston, SC Reviewer NIH-NCI 2005 ZRG-1 MOSS D13 for small business Reviewer NIH grant applications 2005 Molecular and Cellular Endocrinology Reviewer NIH-NCI Study Section (MCE) 2005, 2006 Development of methods for in vivo Reviewer NIH-NCI imaging and bioengineering research Study Section (ZRG1) 2006 Subcommittee A – Cancer Centers Reviewer NIH-NCI NCI Initial Review Group NCI-A RTRB-H (L1) 2006 NCI Renal Cancer Biomarkers Workshop Member NIH-NCI 2007 Cellular & Tissue Biology Special Reviewer NIH-NCI Emphasis Panel 2007, 2008 Basic Mechanisms of Cancer Therapeutics Reviewer NIH-NCI Study Section (BMCT) 2007 Diabetes Endocrinology Research Centers Reviewer NIH-NIDDK & Diabetes Research and Training Centers Special Emphasis Panel International: Year Name of Committee Role Institution 1986 Research Grants of The Sir External Reviewer The Sir Mortimer B. Mortimer B. Davis-Jewish General Davis-Jewish Hospital General Hospital, Montreal, Canada 1998, 1999, Research Grants of the Flanders Foundation External Reviewer Flanders Foundation 2001 for Scientific Research, Belgium for Scientific Research, Belgium 2002 Large Scale Project Grants for External Reviewer Genome Canada Genome Canada 2003 Arthritis Research Campaign External Reviewer Chesterfield, UK 2004 Large Scale Project Grants for External Reviewer Genome Canada Genome Canada 2007 President of Ireland Young Researcher External Reviewer Science Award Foundation of Ireland 2007 Research Grant External Reviewer Israel Science Foundation 2007 Project Grant External Reviewer Cancer Research UK 2007 Research Hospital Fund Large-Scale External Reviewer Canada Foundation Institutional Endeavours Competition for Innovation Canada Major Committee Assignments: Local: Year Name of Committee Role Institution 1992- Thesis Defenses Member Harvard Medical School 1999- Harvard Cancer Center, Member Harvard Medical Prostate Cancer Program School 1999- Harvard Cancer Center, Member Harvard Medical Breast Cancer Program School 2001 Angiogenesis, Invasion and Metastasis Member Harvard Medical program School 2002- Thesis Committee Member Harvard Medical School 2003 Thesis Committee Member HST/MIT 2003- HST PhD Admission Committee Member HST/MIT 2003- Womens Health Research Community Affiliated Harvard Medical Investigator School 2003- Harvard Cancer Center, Member Harvard Medical Renal Cancer Program School 2004 Core Planning Committee Member Beth Israel Deaconess Medical Center 2004- Harvard Cancer Center, Member Harvard Medical Ovarian Cancer Program School 2004- Dana Farber/Harvard Cancer Center, Member Harvard Medical Scientific Council School 2005- Planning Committee, Center for Member Beth Israel Individualized Medicine Deaconess Medical Center 2007- Renal Cancer SPORE Governance Member Harvard Medical Committee School 2008- Cancer Genetics Program Member Beth Israel Deaconess Medical Center National: Year Name of Committee Role 2003 BioArrays 2003, New York, NY Organizing Committee 2005 IBC’s Global Conference on Early Organizing Committee Efficacy Assessment for Chronic Diseases, Boston, MA International: Year Name of Committee Role Institution 2003 Thesis Defense Examiner Monash University, Victoria, Australia Professional Societies: Year Society Role 1994- American Society for Microbiology Member 1995-1998 American Diabetes Association Member 1996-1999 Association of Immunologists Member 1997- American Association for the Member Advancement of Science 2004- American Society for Biochemistry & Member Molecular Biology 2005- American Association for Cancer Research Member 2005- Proteome Society Member 2005- Protein Society Member 2005- Gerson Lehrman Group Healthcare GLG Scholar Council 2005- HUPO Member Journal Review and Editorial Boards: 1990- Ad hoc reviewer for New England Journal of Medicine, Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Oncogene, Biochemical Journal, Journal of Biological Chemistry, Molecular and Cellular Biology, Human Gene Therapy, Journal of Clinical Investigation, Urological Research, Journal of Virology, International Journal of Cancer, Neoplasia, Journal of Proteome Research, Journal of Cellular Biochemistry, Journal of the National Cancer Institute, Expert Opinion on Therapeutic Targets, Apoptosis, Blood, European Journal of Cancer, BMC Molecular Biology, Journal of Pathology, The American Journal of Pathology, Physiological Genomics, Journal of Cellular and Molecular Medicine 2006- Faculty Member, Faculty of 1000 Medicine, Oncology, Section of Genitourinary Cancers 2006- Editor-in-Chief, Drug Targets Insights, Journal, Libertas Academica Publisher 2007- Associate Editor, Cancer Research, Journal, AACR 2008 Editor-in-Chief, Open Proteomics Journal, Journal, Bentham Science Publishers Awards and Honors: Year Name of Award 1983 UICC-International Cancer Research Technology Transfer (ICRETT) Fellowship 1984 Feinberg Graduate School Award for achievements in Ph.D. studies 1985 Leukemia Society of America Fellowship 1995 American Diabetes Association Research Award 1996 Juvenile Diabetes Foundation Research Award 1997, 1998 The Brain Tumor Society Research Award and The Alexis A. Boss Chair of Research 1998 CaP CURE Research Award 2007 Prostate Cancer Foundation Research Award Regional, National, or International Contributions a. Invited Presentation 1983- multiple lectures at EMBL, Heidelberg; German Cancer Research Center, Heidelberg; The Mount Sinai Medical Center, New York; New York University Medical Center, New York; Max Planck Institute, Tuebingen; University of Uppsala, Uppsala; University of San Francisco; University of Geneva, Geneva; Swiss Institute for Experimental Cancer Research, Epalinges; NIH, Bethesda; Wistar Institute, Philadelphia; Merck, Montreal; American Cyanamid, New Jersey; Ely Lilly, Indianapolis 1984 invited lecture International Symposium on Mode of action of growth factors, Paris, France 1985 invited lecture International Symposium on Applied Immunology, Axams, Austria 1985 invited lecture Symposium of the Israeli Society for Microbiology on Oncogenes and Cancer, Rehovot, Israel 1986 session chairman, invited lecture First International Congress on Cancer and Hormones, Rome, Italy 1986 invited lecture Third International Symposium on Local Immunity, Paris, France 1988 invited lecture Ares-Serono Symposium: International Meeting of Endocrinology under 35, Florence, Italy 1988- multiple lectures at Brigham and Women's Hospital, Children's Hospital, Center for Blood Research, Beth Israel Deaconess Medical Center, Boston University Medical Center, New England Medical Center, Dana Farber Cancer Institute 1993 invited lecture Keystone Symposium on Transcription Factors, Regulation and Differentiation, Keystone, Colorado 1993 invited lecture Symposium of the Brazilian Immunological Society, Sao Paulo, Brazil 1996 invited lecture American Association of Immunologists, New Orleans, Louisiana 1998 Endocrine Grand Round Boston University 1998 invited lecture BIDMC Cancer Center Retreat, Woods Hole, Massachusetts 1993, 1998 invited lectures University of Sao Paulo, Federal University of Rio De Janeiro, and INCA, Rio de Janeiro 1999 invited lecture International conference on gene therapy and molecular biology and medicine, Agia Pelagia, Crete, Greece 1999 invited lecture CaP CURE Sixth Annual Scientific Retreat, Incline Village, Nevada 2000 invited lecture MICROMAX-6 months later, Boston, Molecular Diagnostics Meets Therapeutics 2001 invited lecture Genomic approaches to human disease, Boston, Massachusetts 2001 invited lecture Chips to Hits 2001, San Diego, California 2001 invited lecture American Society of Nephrology, San Francisco, California 2002 session chairman, invited lecture Molecular Diagnostics Meets Therapeutics, Boston, Massachusetts 2002 invited lecture Biomicrotechnology Business Summit, San Francisco, California 2002 invited lecture Affymetrix 1st Annual Core Directors Symposium, New York, New York 2003 session chairman, invited lecture First Annual Melanoma Research Congress, Philadelphia, Pennsylvania 2003 invited lecture Macroresults for Microarrays: An Array of Possibilities, Boston, Massachusetts 2003 invited lecture American Transplant Congress, Washington, DC 2003 invited lecture Affymetrix User Group Meeting, San Diego, California 2003 invited lecture 6th World Congress on Inflammation, Vancouver, Canada 2003 invited lecture Prostate Cancer SPORE Retreat, Newport, RI 2003 Scientific advisor, session chairman, invited lecture BioArrays 2003, New York, NY 2003 invited lecture XXV Annual meeting of the ISHR, Mystic, CT 2003 invited lecture 3rd International human tissues for drug discovery through preclinical research, Boston, MA 2004 invited lecture 12th SPORE Investigators’ Workshop, Baltimore, MD 2004 invited lecture Keystone Symposium on NF-kappaB, Snowbird, UT 2004 invited participant 10th Prouts Neck Prostate Cancer Meeting, Prouts Neck, ME 2004 invited lecture Renal and Prostate Cancer SPORE Retreat, Newport, RI 2004 invited lecture Center for Faculty Development Course, “Achieving academic success on the Investigator Criteria: A review of the process and advice for scientistsâ€, Boston, MA 2005 Scientific advisor, session chairman, invited lecture IBC’s Global Conference on Early Efficacy Assessment for Chronic Diseases, Boston, MA 2005 invited lecture Ciphergen User’s Meeting, Newport, RI 2005 invited lecture Early Stage Life Sciences Conference, Boston, MA 2005 invited lecture Proteome Society Meeting, Cambridge, MA 2005 invited lecture Research for Residents Course, Boston, MA 2005 invited lecture Center for Faculty Development Leadership Course, Cambridge, MA 2005 invited lecture Center for Faculty Development Course, “Achieving academic success on the Investigator Criteria: A review of the process and advice for scientistsâ€, Boston, MA 2006 invited plenary lecture, session chairman Microarrays in Medicine, Boston, MA 2006 invited lecture Regional Renal Cancer Symposium: Recent Advances in the Biology and Treatment of Renal Cell Carcinoma, Boston, MA 2006 invited lecture Innovations and Challenges in Renal Cancer, Cambridge, MA 2006 invited lecture WEST Showcase 2006, Boston, MA 2006 invited lecture American Society of Nephrology, San Diego, CA 2006 invited lecture 16th Annual Irwin M. Arias, MD, Symposium on „Bridging Basic Science and Liver Diseaseâ€, Boston, MA 2006 invited lecture NCI Renal Cancer Biomarkers Workshop, Bethesda, MD 2007 invited lecture 3rd USHUPO Meeting, Seattle, WA 2007 invited Presenter Prostate Cancer Foundation Fourteenth Scientific Retreat, Incline Village, Nevada 2007 invited Presenter IMPACT Innovative Minds in Prostate Cancer Today DOD-CDMRP, Atlanta, Georgia 2007 invited discussant Beyond genomics: The latest in proteomics and metabolomics for population research, Boston, MA 2008 invited lecture Bio-IT World Conference and Expo, Boston, MA 2008 invited lecture GOT Summit: Ninth Annual Microarrays in Medicine, Boston, MA 2008 invited lecture GOT SAummit: Proteomics Tools for Diagnostics, Boston, MA 2008 invited lecture 4th Annual Advances in Microarray Technology Conference, Barcelona, Spain 2008 invited lecture Ets transcription factor Symposium, Boston, MA 2008 invited lecture Tri-institutional Prostate Cancer Program Retreat, Newport, RI 2008 invited lecture 44th EASD Annual Meeting, Rome, Italy b. Professional and Educational Leadership Role 1986 The Catholic University of America, Washington D. C. Oncogene course Instructor 2001 IBC Scientific Advisory Board Molecular Diagnostics Meets Therapeutics Conference Organizer 2005 IBC Scientific Advisory Board Global Conference on Early Efficacy Assessment for Chronic Diseases Organizer |
Major Collaborative Activities
| As director of the BIDMC Genomics Center and director of the Dana Farber/Harvard Cancer Center Proteomics Core we have established major collaborative studies with investigators at all major Harvard associated institutions including among others Lew Cantley, Brad Lowell, Olivier Kocher, Glen Rosen, William Aird, Frank Sellke,Ananth Karumanchi, Aria Olumi, Nezam Afdhal, Peter Oettgen, Alan Rigby, Mary Goldring, Steven Cannistra, Andrew Keates, Alex Toker, Vikas Sukhatme, Terry Strom, Bing Lim, Harold Dvorak, Jeffrey Flier, Jinrong Zhou,and Barbara Kahn at the BIDMC, with Charles Stiles, Jerry Ritz, Ken Anderson and Constantine Mitsiades at DFCI, with Isaac Kohane, Judah Folkman, Asher Schachter and Peter Hauschka at Childrens Hospital, with Susan Hankinson at the Channing LAboratory, and with Alice Brown, Ravi Thadhani, and Michael Detmar at the MGH. As a director of the DF/HCC Cancer Proteomics Core DF/HCC investigators from all major Harvard institutions are performing their cancer proteomics studies at the BIDMC Genomics Center. |
Investigator's Lab Web Site
| Research Lab URL | Libermann Research Lab |
| Harvard Catalyst Site: | Libermann Harvard Catalyst Web Site |
